Cancers, Vol. 13, Pages 1643: Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Cancers, Vol. 13, Pages 1643: Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Cancers doi: 10.3390/cancers13071643
Authors:
Prahathishree Mohanavelu
Mira Mutnick
Nidhi Mehra
Brandon White
Sparsh Kudrimoti
Kaci Hernandez Kluesner
Xinyu Chen
Tim Nguyen
Elaina Horlander
Helena Thenot
Vamsi Kota
Cassie S. Mitchell
Tyrosine kinase inhibitors (TKIs) are the frontline therapy for BCR-ABL (Ph+) chronic myeloid leukemia (CML). A systematic meta-analysis of 43 peer-reviewed studies with 10,769 CML patients compared the incidence of gastrointestinal adverse events (GI AEs) in a large heterogeneous CML population as a function of TKI type. Incidence and severity of nausea, vomiting, and diarrhea were assessed for imatinib, dasatinib, bosutinib, and nilotinib. Examination of combined TKI average GI AE incidence found diarrhea most prevalent (22.5%), followed by nausea (20.6%), and vomiting (12.9%). Other TKI GI AEs included constipation (9.2%), abdominal pain (7.6%), gastrointestinal hemorrhage (3.5%), and pancreatitis (2.2%). Mean GI AE incidence was significantly different between TKIs (p < 0.001): bosutinib (52.9%), imatinib (24.2%), dasatinib (20.4%), and nilotinib (9.1%). Diarrhea was the most prevalent GI AE with bosutinib (79.2%) and dasatinib (28.1%), whereas nausea was most prevalent with imatinib (33.0%) and nilotinib (13.2%). Incidence of grade 3 or 4 severe GI AEs was ≤3% e...
Source: Cancers - Category: Cancer & Oncology Authors: Prahathishree Mohanavelu Mira Mutnick Nidhi Mehra Brandon White Sparsh Kudrimoti Kaci Hernandez Kluesner Xinyu Chen Tim Nguyen Elaina Horlander Helena Thenot Vamsi Kota Cassie S. Mitchell Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Chronic Pain | Constipation | Gastroenterology | Gleevec | Leukemia | Nilotinib | Pain | Pancreatitis | Study | Tasigna